Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Richieri Costa-Pereira syndrome is characterized by short stature, Robin sequence, cleft mandible, pre/postaxial hand anomalies (including hypoplastic thumbs), and clubfoot. It has been described in 14 Brazilian families and in one unrelated French patient. Prominent low set ears and a highly arched palate were also observed. Transmission is autosomal recessive.
Features include always present findings: Short hallux, Microretrognathia, Hypoplasia of the radius, and Micrognathia; and very common findings: Fibular hypoplasia, Narrow mouth, Small hypothenar eminence, and Agenesis of mandibular central incisor and others. 41 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 5 | Radial deviation of the hand, Short phalanx of finger, Tibial deviation of toes |
Head and neck | 5 | Agenesis of mandibular central incisor, High palate, Cleft palate |
Brain and nerves | 2 | Delayed speech and language development, Global developmental delay |
Growth and development | 1 | Short stature |
Voice | 1 | Abnormality of the voice |
Digestive system | 1 | Feeding difficulties |
EIF4A3 encodes eukaryotic translation initiation factor 4A3 (411 aa). ATP-dependent RNA helicase. Involved in pre-mRNA splicing as component of the spliceosome. Highest expression in Cells EBV-transformed lymphocytes (163.0 TPM) and Cells Cultured fibroblasts (156.6 TPM).
Richieri Costa-Pereira syndrome is associated with mutations in the EIF4A3 gene on chromosome 17.
EIF4A3 is classified as a druggable target (Enzyme and Transporter categories) with score 0.0.
Genetic testing for EIF4A3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 4 always present features, 11 very common features, 8 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Richieri Costa-Pereira syndrome.
3 publications have been identified in PubMed for Richieri Costa-Pereira syndrome. Research spans Basic Science / Preclinical (67%) and Review / Meta-Analysis (33%).
van de Velde S (2026). [PMID: 41077824](https://pubmed.ncbi.nlm.nih.gov/41077824/). *Clin Genet*. [Review / Meta-Analysis]
Villa T (2025). [PMID: 41261863](https://pubmed.ncbi.nlm.nih.gov/41261863/). *Nucleic Acids Res*. [Basic Science / Preclinical]
Alsina FC (2024). [PMID: 39182224](https://pubmed.ncbi.nlm.nih.gov/39182224/). *Cell Rep*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 12:23 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Richieri Costa-Pereira syndrome